Rebalancing T Cells in AD: A Conversation With Dr. Emma Guttman-Yassky on Rocatinlimab’s Potential
OX40 and OX40-ligand are getting lots of buzz in the eczema world today, and we can expect to hear lots more about these molecules in 2026 as several agonists make their way through clinical trials, including Amgen and Kyowa Kirin Co., Ltd.’s rocatinlimab. Rocatinlimab is the first and only later-stage T-cell rebalancing therapy that inhibits […]